AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s Yokohama Technical Center.

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks ...

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a ...

Learn how soluble B-cell maturation antigen contributes to the effectiveness of targeted immunotherapies.

Learn how multispecific antibodies can be used for immunotherapy in cancer treatments.

NeuroScientific Biopharmaceuticals Ltd has completed the acquisition of Isopogen WA Ltd, gaining full rights to the StemSmart™ patented stem cell technology.

Keysight’s Open RAN Architect (KORA) solutions powered 11 multi-vendor integration test demonstrations in labs across several countries, validating real-world Open RAN deployments.